The EEF1E1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the EEF1E1 gene in Jurkat human T lymphocyte cells. Generated via CRISPR/Cas9-mediated gene disruption, this loss-of-function model offers a heterogeneous cell pool lacking EEF1E1 expression, enabling functional studies without clonal bias. This product is a versatile tool for investigating EEF1E1??s roles in translation elongation, mTOR signaling, and apoptosis in a T-cell context.
The Jurkat host cell line is an immortalized human T lymphocyte line isolated from an acute lymphoblastic leukemia (ALL) patient. Widely employed in T-cell receptor signaling, apoptosis, and leukemia research, its suspension growth and well-defined signaling pathways provide an ideal system for studying EEF1E1 function in lymphocyte biology and hematological malignancies.
EEF1E1 encodes a subunit of the elongation factor-1 (EF-1) complex, which delivers aminoacyl-tRNAs to the ribosome A site during translation elongation. It forms complexes with EEF1A1, EEF1G, and multisynthetase components AIMP1 and AIMP2. EEF1E1 is regulated by mTORC1 signaling and the MYC transcription factor, linking nutrient sensing to protein synthesis. Disruption of EEF1E1 compromises EF-1 complex integrity, impairing translation elongation and potentially affecting cell growth, proliferation, and apoptosis. Thus, EEF1E1 integrates signals from mTOR and translation machinery, influencing DNA damage responses.
In Jurkat T cells, EEF1E1 knockout impairs translation elongation, potentially reducing protein synthesis and altering expression of survival and proliferation factors. Given the high translational demand in ALL, EEF1E1 disruption may sensitize cells to apoptosis or dampen oncogenic signaling. This model allows dissection of EEF1E1??s roles in translation-dependent leukemic phenotypes and normal T-cell function, and the mTORC1?CEEF1E1 axis offers a platform for testing translation-targeted therapies.
These polyclonal knockout cells are suitable for techniques such as Western blot for EEF1E1 protein, RT-qPCR for mRNA, and genomic sequencing for target-site verification. Functional assays include cell viability, Annexin V apoptosis detection, and puromycin incorporation for protein synthesis rates. Transcriptome and translatome analyses by RNA-seq and ribosome profiling, along with phospho-mTOR and cell cycle flow cytometry, enable comprehensive pathway interrogation. For further details or custom requests, contact Ascent Research.
